During a median treatment duration of @ years , compared with the enalapril alone group , the enalapril-folic acid group had a significant risk reduction in first stroke ( @ % of participants in the enalapril-folic acid group vs @ % in the enalapril alone group ; hazard ratio -LSB- HR -RSB- , @ ; @ % CI , @-@ @ ) , first ischemic stroke ( @ % with enalapril-folic acid vs @ % with enalapril alone ; HR , @ ; @ % CI , @-@ @ ) , and composite cardiovascular events consisting of cardiovascular death , MI , and stroke ( @ % with enalapril-folic acid vs @ % with enalapril alone ; HR , @ ; @ % CI , @-@ @ ) .